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Summary
Objective: Patients with hyperthyroidism lacking autoimmune features but showing diffuse uptake on thyroid scintigram can have either Graves' disease or germline activating TSH receptor (TSHR) mutation. It is important to identify patients with activating TSHR mutation due to treatment implication, but the overlapping clinical features with Graves' disease make it difficult to discriminate these two conditions without genetic testing. Our study aimed to assess the potential of systematic TSHR 
Conclusions:
Activating TSHR mutations are a rare cause of nonautoimmune adult hyperthyroidism. Our study does not support the routine genetic testing in adult patients with hyperthyroidism showing diffuse uptake on scintigraphy but negative TRAb and lacking extrathyroidal manifestations of Graves' disease.
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| INTRODUC TI ON
Activating TSH receptor (TSHR) mutations are a rare cause of nonautoimmune hyperthyroidism, although the true prevalence in adults is unknown. [1] [2] [3] The majority of these cases are familial, with autosomal dominant patterns of inheritance, but mutation can also arise de novo. 8, 9 and only about 25% will have extrathyroidal manifestations, such as thyroid-associated ophthalmopathy. 10 Altogether these data suggest that it is difficult to identify patients with activating TSHR mutation in routine clinical practice without systematic genetic testing. However, utility of this approach is not known. Therefore, we aim to assess the utility of systematic genetic testing for TSHR mutations in adults with hyperthyroidism showing diffuse uptake on thyroid scintigraphy but TRAb negative and lacking extrathyroidal manifestations of Graves' disease.
| SUBJEC TS AND ME THODS

| Study participants
We recruited patients from three endocrine centres (Exeter, Plymouth and Torbay) in the South West, England (UK). The inclusion criteria were as follows: age at recruitment >18 years, biochemically confirmed overt or subclinical hyperthyroidism according to the American Thyroid Association guideline, 11 absence of TRAb, diffuse uptake on the thyroid scintigraphy and Caucasian ethnicity. We excluded patients with any extrathyroidal manifestations of Graves' disease, such as thyroid-associated ophthalmopathy or dermopathy, and patients with any other known cause of hyperthyroidism (eg, toxic nodular disease, thyroiditis and drug-induced thyrotoxicosis).
| Study recruitment
We identified 275 patients from the clinical records who had thy- were reviewed to assess the eligibility of these patients. Of the initial 275 potential participants identified, three had died, 41 had decreased or no uptake on scintigraphy, 98 had patchy/localized uptake, two had Graves' ophthalmopathy, and four had drug-related thyrotoxicosis, and they were therefore excluded. All 127 patients who fulfilled the entry criteria were approached and invited to take part in the study, and 78/127 (61%) were recruited (49 refused or were unable to be contacted directly). We estimated the frequency of activating TSHR mutation in adults with hyperthyroidism lacking overt autoimmunity and diffuse uptake on thyroid scintigraphy to be ~4.5% based on two previous studies. 12, 13 This provided a sample size of 67 to find at least one individual with a mutation at P < 0.05.
| DNA and data collection
We collected one-off blood or saliva sample for DNA extraction.
Demographics and other clinical features were collected from the clinical records. If an individual had multiple episodes of the thyrotoxicosis, the data for the episode during which thyroid scintigraphy and TRAb were performed were used in the study.
All three centres have been using a second-generation enzyme- 
| Data analysis
| RE SULTS
| Study cohort characteristics
The clinical characteristics of the study cohort are shown in Table 1 .
The median age at diagnosis of hyperthyroidism was 52 years, 76%
were female, and 42% had a palpable diffuse goitre. None had thyroid-associated ophthalmopathy, dermopathy or TRAb, all had diffuse uptake on thyroid scintigraphy, and 35% had a family history of thyrotoxicosis.
| Analysis of TSHR variants
Genetic analysis identified 11 patients with four variants inTSHR ( TA B L E 1 Clinical characteristics of the study cohort spot, not conserved and seen in five patients in gnomAD (Table 2) .
Based on the frequency of this variant in gnomAD, for this variant to be pathogenic, monogenic disease would have to be seen in one in 5000 population, which is far more common than the estimated prevalence of hyperthyroidism due to activating TSHR mutations (~<1:15 000 children in Denmark). 12, 20 None of the previously published pathogenic activating TSHR mutations are seen in gnomAD.
Furthermore, the proband with this variant in our study was diagnosed at 60 years of age and had no family history of thyrotoxicosis. She also remitted after 18 months of antithyroid drug treatment which is unlikely if she had activating TSHR gene mutation.
| D ISCUSS I ON
Our study identified that the systematic assessment for activating TSHR mutations in adult patients with hyperthyroidism with diffuse uptake on scintigraphy, negative TRAb and absence of extrathyroidal manifestations of Graves' disease (such as thyroid-associated ophthalmopathy or dermopathy) did not identify a single case. Our study, therefore, is unable to support the routine genetic testing for TSHR mutations in these patients.
This is the largest study in adult Caucasian patients with hyperthyroidism with diffuse goitre and lacking overt autoimmunity, and we did not find any individuals with a pathogenic variant in theTSHR gene. Our study results differ from a previous study in adult Japanese hyperthyroid patients with diffuse goitre and without TRAb (n = 89). 13 This study found activating TSHR mutations in four patients, giving a prevalence of 4.5%. This discrepancy in the results may be due to different populations characteristics;
for example, our study participants were older, median age 52 vs 40 years. 13 The high frequency in the Japanese population may be due to founder effects as seen in other monogenic diseases in this population. 21 The negative results in our study may also be due to a type II error (false negative), although we were powered to detect a 4.5% frequency with 95% confidence. This suggests that the accurate assessment of prevalence of activating TSHR mutation in adult Caucasian patients may need a larger sample size. For example, Nishihara et al found only 89 patients with diffuse goitre and lacking overt autoimmunity from 24 623 hyperthyroid patients referred to them over 9 years. 13 Our results suggest that routine screening forTSHR gene may not be a useful practice in adult Caucasian patients with hyperthyroidism lacking overt autoimmunity and diffuse goitre due to the rarity of the disease. The European Thyroid Association (ETA) have previously issued recommendations on when and whom to select for genetic testing for TSHR. 3 One-third of our cohort had a family history of thyrotoxicosis, and fulfilled the ETA criteria for genetic testing for TSHR mutation. 3 Our results do not support routine genetic testing in adult onset hyperthyroidism even in the presence of family history of thyrotoxicosis; however, it may be useful for families with multigenerational history of thyrotoxicosis. Our results are not applicable to children, and these patients should TA B L E 2 TSH receptor (TSHR) variants identified in the study cohort This is supported by the study in Danish children that showed 6% of children with nonautoimmune hyperthyroidism have activating TSHR mutation. 12 We acknowledge several study limitations: we only recruited 61% patients from the eligible cohort, and a larger sample size would have increased the power to identify a lower frequency of activating TSHR mutation. We did not have data on Doppler thyroid ultrasound or thyroid-stimulating immunoglobulin to exclude Graves' disease. Although these two tests would have reduced the number of eligible patients, it would not have changed the results of our study due to the inclusive nature of our study eligibility criteria. We excluded patients with multinodular goitre in our study as it is seen in <15% of individual with activating TSHR mutation. This along with relatively common occurrence of nongenetic multinodular goitre in adult population would have provided very low positive predictive value of multinodular goitre to identify TSHR mutation. 2 We also did not take the treatment history of patients (eg, relapse after antithyroid drug treatment) into consideration when selecting potential participants as we wanted to establish the utility of genetic testing at the time of diagnosis during routine clinical care.
In conclusion, our systematic assessments of adult Caucasian patients with hyperthyroidism showed that activating TSHR gene mutations are a rare cause of nonautoimmune hyperthyroidism. Our results do not support the routine genetic testing for adult patients with hyperthyroidism showing diffuse uptake on scintigraphy but lacking autoimmune features of Graves' disease.
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